For children who are not seriously ill or injured, other solutions can be considered, such as the 811 line or walk-in clinics,' one medical director said.
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).